| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | NEUTRAL | NEUTRAL | NEUTRAL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | N/A | N/A | N/A | 23.71▲ | 24.31▼ |
| MA10 | N/A | N/A | N/A | 23.63▲ | N/A |
| MA20 | N/A | N/A | N/A | 24.18▼ | N/A |
| MA50 | N/A | N/A | N/A | N/A | N/A |
| MA100 | N/A | N/A | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | N/A | N/A | N/A | N/A | N/A |
| RSI | N/A | N/A | N/A | 32.446▼ | N/A |
| STOCH | N/A | N/A | N/A | 48.034 | N/A |
| WILL %R | N/A | N/A | N/A | -74.185 | N/A |
| CCI | N/A | N/A | N/A | -17.014 | N/A |
|
Friday, April 26, 2024 05:35 AM
Select "Add to Compare" to begin comparing Stocks, ETFs, Mutual Funds and more.
|
|
Monday, April 22, 2024 12:04 PM
FDA approved Mirum Pharmaceuticals' Limvarli for treatment of cholestatic pruritus in patients with PFIC. Learn why I rate MIRM stock a buy.
|
|
Wednesday, April 17, 2024 08:00 AM
Across the recent three months, 9 analysts have shared their insights on Mirum Pharmaceuticals (NASDAQ:MIRM), expressing a variety of opinions spanning from bullish to bearish. The following table ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 26/04/24 | 23.7678 | 23.7678 | 23.7678 | 23.7678 | 31 |
| 25/04/24 | 23.56 | 23.6237 | 23.56 | 23.6237 | 102 |
| 24/04/24 | 23.7648 | 23.7648 | 23.7648 | 23.7648 | 1,202 |
| 23/04/24 | 23.56 | 23.7007 | 23.56 | 23.7007 | 1,202 |
| 22/04/24 | 23.7081 | 23.7081 | 23.7081 | 23.7081 | 166 |
| 19/04/24 | 23.3743 | 23.3743 | 23.3743 | 23.3743 | 10 |
| 18/04/24 | 23.6609 | 23.6609 | 23.6609 | 23.6609 | 10 |
| 17/04/24 | 23.448 | 23.448 | 23.448 | 23.448 | 5 |
| 16/04/24 | 23.4895 | 23.4895 | 23.4895 | 23.4895 | 155 |
| 15/04/24 | 23.728 | 23.728 | 23.728 | 23.728 | 21 |
|
|
||||
|
|
||||
|
|